William Reichardt, DO
Internal Medicine · Traverse City, MINPI 1194174789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $382 of the $594 with a category attached, or 64.3%. It is spread thinly across 18 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2021 at $266 and has fallen 93.9% since, to $16 in 2023.
Across 22 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$114
- AstraZeneca$100
- Gilead$55
- Pharmacyclics LLC, An Abbvie Company$46
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31
- Seagen Inc.$30
- plus $218 from 12 others
What the payments were for
- Food & beverage$38264%
- Education$21236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $114 |
| AstraZeneca | 1 | $100 |
| Gilead | 2 | $55 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Seagen Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Emmaus Medical, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$594 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 26 | $354,352 |
| XtandiEnzalutamide | 15 | $239,073 |
| Abiraterone Acetate | 52 | $29,319 |
| Imatinib Mesylate | 23 | $5,833 |
| Anastrozole | 79 | $3,226 |
| Prochlorperazine Maleate | 56 | $936 |
| Hydroxyurea | 27 | $698 |
| Prednisone | 109 | $643 |
| Dexamethasone | 70 | $537 |
| Ondansetron OdtOndansetron | 28 | $395 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 26 | $285 |
| Tamoxifen Citrate | 14 | $262 |
| Ondansetron Hcl | 48 | $241 |
| Olanzapine | 56 | $170 |
| Potassium Chloride | 14 | $140 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Traverse City
- Steven LamieTraverse City$54K
- Adrienne EdgrenTraverse City$47K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.